Citigroup
XLRN

Citigroup’s Acceleron Pharma XLRN Stock Holding History

Citigroup’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-6,400
Closed -$575K – 7764
2020
Q1 		$575K Sell
6,400
-7,100
-53% -$552K ﹤0.01% 3742
2019
Q4 		$716K Buy
13,500
+2,800
+26% +$128K ﹤0.01% 4092
2019
Q3 		$423K Buy
10,700
+2,400
+29% +$104K ﹤0.01% 4500
2019
Q2 		$341K Sell
8,300
-4,500
-35% -$186K ﹤0.01% 4807
2019
Q1 		$596K Buy
12,800
+8,900
+228% +$391K ﹤0.01% 3994
2018
Q4 		$170K Sell
3,900
-2,500
-39% -$125K ﹤0.01% 5184
2018
Q3 		$366K Buy
+6,400
New +$315K ﹤0.01% 4641
2017
Q4 		– Sell
-40,000
Closed -$1.49M – 7701
2017
Q3 		$1.49M Buy
+40,000
New +$1.39M ﹤0.01% 2961

Citigroup's XLRN Position: Q4 2021 in Review

Citigroup sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 248,768 shares — an estimated $42.8M sold.

Citigroup first reported a position in XLRN in Q4 2013 and held it in 32 quarters. The position peaked at $42.8M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • Citigroup reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • Citigroup sold 248,768 Acceleron Pharma shares in Q4 2021, an estimated $42.8M.
  • Citigroup first reported a position in Acceleron Pharma in Q4 2013 and held it in 32 quarters.
  • Citigroup's Acceleron Pharma position peaked at $42.8M in Q3 2021.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Citigroup's 13F filing for Q4 2021, filed 10 Feb 2022.